CELG
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FCELG.O%2Fkey-developments%2Farticle%2F2517291&ei=oYaaUpDCBOTX0QGcJA&usg=AFQjCNGFvAF0wF5YFLBy1F06ujhU6Bqd3Q
AnaptysBio Announces Strategic Antibody Discovery Partnership With Celgene Corporation
Monday, 9 Apr 2012 08:00am EDT
AnaptysBio, Inc., a privately-held therapeutic antibody company, announced a strategic partnership with Celgene Corporation to develop antibodies against multiple therapeutic targets. Under this partnership, AnaptysBio is responsible for generating therapeutic antibodies to oncology and inflammation-related targets using SHM-XEL platform. Celgene will receive worldwide rights to develop and commercialize antibodies discovered by AnaptysBio under the terms of the partnership. In addition to an upfront payment, AnaptysBio is due to receive preclinical and clinical payments from Celgene, as well as royalties upon sales of each product derived from the partnership.Â 
